Non-Current Liabilities

Total Liabilities

Ciena Total Liabilities increased by 303.8% to $30.93M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 98.9%, from $2.78B to $30.93M. Over 5 years (FY 2020 to FY 2025), Total Liabilities shows a downward trend with a -65.9% CAGR.

Analysis

StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryLeverage
SignalContext dependent
VolatilityStable
First reportedQ4 2024
Last reportedQ1 2026

How to read this metric

A high level of total liabilities relative to equity indicates a more leveraged capital structure and higher financial risk.

Detailed definition

The aggregate of all current and non-current debts and obligations owed by the company to external parties. It represent...

Peer comparison

Analyzed alongside Total Assets to determine the Debt-to-Asset ratio, which is a standard measure of solvency across all industries.

Metric ID: total_liabilities

Historical Data

19 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Value$1.73B$1.85B$2.09B$2.18B$2.23B$2.36B$2.83B$2.87B$2.78B$2.75B$2.67B$2.73B$2.68B$2.83B$2.78B$2.88B$2.96B$7.66M$30.93M
QoQ Change+6.6%+13.0%+4.6%+2.4%+5.5%+20.3%+1.2%-3.2%-0.8%-3.0%+2.4%-1.8%+5.3%-1.6%+3.7%+2.7%-99.7%+303.8%
YoY Change+29.0%+27.7%+35.9%+31.4%+24.3%+16.8%-5.8%-4.6%-3.3%+2.6%+4.1%+5.4%+10.3%-99.7%-98.9%
Range$7.66M$2.96B
CAGR-59.1%
Avg YoY Growth-1.6%
Median YoY Growth+5.4%

Frequently Asked Questions

What is Ciena's total liabilities?
Ciena (CIEN) reported total liabilities of $30.93M in Q4 2025.
How has Ciena's total liabilities changed year-over-year?
Ciena's total liabilities decreased by 98.9% year-over-year, from $2.78B to $30.93M.
What is the long-term trend for Ciena's total liabilities?
Over 5 years (2020 to 2025), Ciena's total liabilities has grown at a -65.9% compound annual growth rate (CAGR), from $1.67B to $7.66M.
What does total liabilities mean?
The total amount of money the company owes to everyone, both now and in the future.